Cart
sales@molnova.com
Masitinib mesylate
CAS No. 1048007-93-7
Masitinib mesylate( AB1010 mesylate | AB-1010 mesylate | AB 1010 mesylate )
Catalog No. M10237 CAS No. 1048007-93-7
A potent tyrosine kinase inhibitor targeting c-Kit and PDGFR with IC50 of 0.15 and 0.05 uM in cell based assays.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 27 | Get Quote |
|
| 10MG | 42 | Get Quote |
|
| 25MG | 63 | Get Quote |
|
| 50MG | 78 | Get Quote |
|
| 100MG | 132 | Get Quote |
|
| 200MG | 213 | Get Quote |
|
| 500MG | 353 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameMasitinib mesylate
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent tyrosine kinase inhibitor targeting c-Kit and PDGFR with IC50 of 0.15 and 0.05 uM in cell based assays.
-
DescriptionA potent tyrosine kinase inhibitor targeting c-Kit and PDGFR with IC50 of 0.15 and 0.05 uM in cell based assays; also inhibits Lyn, and to a lesser extent, FGFR3, and inhibits KIT gain-of-function mutants V559D (IC50=3.0 nM) and Δ27 mouse mutant (IC50=5 nM); dose-dependently inhibits SCF-induced cell proliferation in Ba/F3 cells expressing human wild-type KIT (IC50=150 nM); inhibits tumour growth in vivo.Prostate cancer Phase 3 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsAB1010 mesylate | AB-1010 mesylate | AB 1010 mesylate
-
PathwayAngiogenesis
-
Targetc-Kit
-
Recptorc-Kit
-
Research AreaCancer
-
IndicationProstate Cancer
Chemical Information
-
CAS Number1048007-93-7
-
Formula Weight594.748
-
Molecular FormulaC29H34N6O4S2
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 30 mg/mL
-
SMILESO=C(NC1=CC=C(C)C(NC2=NC(C3=CC=CN=C3)=CS2)=C1)C4=CC=C(CN5CCN(C)CC5)C=C4.OS(=O)(C)=O
-
Chemical NameBenzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-, methanesulfonate (1:1)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Dubreuil P, et al. PLoS One. 2009 Sep 30;4(9):e7258.
2. Humbert M, et al. Allergy. 2009 Aug;64(8):1194-201.
3. Tebib J, et al. Arthritis Res Ther. 2009;11(3):R95.
molnova catalog
related products
-
DCC-2618
DCC-2618 (Ripretinib, DCC2618) is a potent, oral inhibitor of singly and doubly mutated KIT with IC50 of WT (IC50=4 nM), V654A (8 nM), T670I (18 nM), D816H (5 nM).
-
Cistanoside A
Cistanoside A possesses protective activities on CCl4 induced hepatotoxicity in mice, which is involved with increasing free radicals clearing activities.
-
N-Desethylsunitinib ...
N-Desethylsunitinib hydrochloride is a major and pharmacologically active metabolite of sunitinib, which is potent, ATP-competitive VEGFR, PDGFRβ, and KIT inhibitor.
